Reward Deficiency Syndrome (RDS): A Common Neurogenetic Trait/State of All Addictions: Is this the new DSM?

Area of Science:

• Neuroscience
• Psychiatry
• Genetics

Background:

• Current psychiatric research often assumes discrete diagnostic categories, but empirical boundaries are porous.
• Reward Deficiency Syndrome (RDS) offers a transdiagnostic framework for addiction, unifying substance and behavioral types.
• Large-scale genetic studies support dopaminergic dysregulation as a key factor in RDS vulnerability.

Purpose of the Study:

• To propose a biphasic prevention and treatment strategy for substance and non-substance addictive behaviors based on RDS.
• To explore the role of dopaminergic neurotransmission in addiction and recovery.
• To investigate potential interventions targeting dopamine receptors and signaling.

Main Methods:

• Review of existing literature on neuroscience, psychiatry, and genetics related to addiction.
• Analysis of genome-wide association and pharmacogenomic findings.
• Conceptual framework for a biphasic treatment strategy involving dopamine receptor modulation and signaling restoration.

Main Results:

• Dopaminergic dysregulation is implicated in RDS vulnerability across diverse addictive behaviors.
• Overlapping genetic polymorphisms in conditions like DSM-5 disorders converge on dopaminergic pathways.
• Both acute harm-reduction and long-term recovery may depend on modulating dopamine signaling in the nucleus accumbens.

Conclusions:

• A biphasic approach balancing short-term modulation and long-term restoration of dopamine signaling is proposed for addiction treatment.
• Individuals with specific genetic profiles (e.g., serotonergic/dopaminergic deficits, high COMT activity) may be more susceptible to addiction.
• Strategies to increase D2 receptor expression and naturalistic dopaminergic repletion may offer safer, long-term recovery pathways for RDS.